Those prescribed a sulfonylurea had an increased risk of HCC compared to never users, although the association was attenuated after adjusting for comorbidities (alcoholic liver disease, chronic viral hepatitis, LC, chronic lower respiratory disease, previous cancer, and Charlson comorbidity index), household income level, residential area, aspirin use, statin use, and other anti-diabetic agent (insulin, glinide, metformin, thiazolidinedione, and DPP4 inhibitor) use (AOR = 1.65, 95% CI = 0.90–3.02). Here, DPP4 is linked to hepatocellular carcinoma.